Bayer AG has entered a global exclusive license and collaboration with Kumquat Biosciences to develop and commercialize Kumquat's KRAS G12D inhibitor, targeting one of the most prevalent oncogenic mutations in cancer. This deal, worth up to $1.3 billion, aims to address pancreatic, colorectal, and lung cancers, which frequently harbor the difficult-to-drug KRAS G12D variant. Following FDA clearance of Kumquat's IND application, Kumquat will conduct the Phase Ia study, while Bayer assumes responsibility for subsequent development and commercialization. This partnership exemplifies pharmaceutical giants' ongoing efforts to tackle KRAS-driven malignancies, complementing Bayer's precision oncology portfolio.